RT Journal Article
SR Electronic
T1 <em>Klebsiella pneumoniae</em> mutants resistant to ceftazidime/avibactam plus aztreonam, imipenem/relebactam, meropenem/vaborbactam and cefepime/taniborbactam
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.11.21.469431
DO 10.1101/2021.11.21.469431
A1 Naphat Satapoomin
A1 Punyawee Dulyayangkul
A1 Matthew B. Avison
YR 2021
UL http://biorxiv.org/content/early/2021/11/22/2021.11.21.469431.abstract
AB Using modified Klebsiella pneumoniae clinical isolates, we show that ramR plus ompK36 mutation together with production of the V239G variant KPC-3 confirs resistance to ceftazidime/avibactam plus aztreonam, imipenem/relebactam and meropenem/vaborbactam, but not cefepime/taniborbactam. This is because the V239G variant does not generate collateral β-lactam susceptibility as do many other KPC-3 variants associated with ceftazidime/avibactam resistance. Additional mutation of ompK35 and carriage of a plasmid expressing the OXA-48-like carbapenemase OXA-232 was required to confer cefepime/taniborbactam resistance.Competing Interest StatementThe authors have declared no competing interest.